Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability
Influenza A virus (IAV) poses a threat to patients receiving immunosuppressive medications since they are more susceptible to infection with severe symptoms, and even death. Understanding the direct effects of immunosuppressants on IAV infection is critical for optimizing immunosuppression in these patients who are infected or at risk of influenza virus infection. We profiled the effects of 10 immunosuppressants, explored the antiviral mechanisms of immunosuppressants, and demonstrated the combined effects of immunosuppressants with the antiviral drug oseltamivir in IAV-infected cell models. We found that mycophenolic acid (MPA) strongly inhibits viral RNA replication via depleting cellular guanosine pool. Treatment with 6-Thioguanine (6-TG) promoted viral protein degradation through a proteasomal pathway. Filgotinib blocked mRNA splicing of matrix protein 2, resulting in decreased viral particle assembly. Furthermore, combined treatment with immunosuppressants and oseltamivir inhibits IAV viral particle production in an additive or synergic manner. Our results suggest that MPA, 6-TG, and filgotinib could be the preferential choices for patients who must take immunosuppressants but are at risk of influenza virus infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Virulence - 15(2024), 1 vom: 09. Feb., Seite 2301242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Xin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
20O93L6F9H |
|---|
| Anmerkungen: |
Date Completed 07.02.2024 Date Revised 11.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21505594.2023.2301242 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366613049 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366613049 | ||
| 003 | DE-627 | ||
| 005 | 20240211231949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21505594.2023.2301242 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM366613049 | ||
| 035 | |a (NLM)38170681 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2024 | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Influenza A virus (IAV) poses a threat to patients receiving immunosuppressive medications since they are more susceptible to infection with severe symptoms, and even death. Understanding the direct effects of immunosuppressants on IAV infection is critical for optimizing immunosuppression in these patients who are infected or at risk of influenza virus infection. We profiled the effects of 10 immunosuppressants, explored the antiviral mechanisms of immunosuppressants, and demonstrated the combined effects of immunosuppressants with the antiviral drug oseltamivir in IAV-infected cell models. We found that mycophenolic acid (MPA) strongly inhibits viral RNA replication via depleting cellular guanosine pool. Treatment with 6-Thioguanine (6-TG) promoted viral protein degradation through a proteasomal pathway. Filgotinib blocked mRNA splicing of matrix protein 2, resulting in decreased viral particle assembly. Furthermore, combined treatment with immunosuppressants and oseltamivir inhibits IAV viral particle production in an additive or synergic manner. Our results suggest that MPA, 6-TG, and filgotinib could be the preferential choices for patients who must take immunosuppressants but are at risk of influenza virus infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunosuppressants | |
| 650 | 4 | |a Influenza A virus | |
| 650 | 4 | |a antiviral agents | |
| 650 | 4 | |a immunosuppression | |
| 650 | 7 | |a Oseltamivir |2 NLM | |
| 650 | 7 | |a 20O93L6F9H |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Pu, Feiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xuanye |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Xili |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jiayou |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Nian, Xuanxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Zhongren |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiao-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiao-Ming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virulence |d 2010 |g 15(2024), 1 vom: 09. Feb., Seite 2301242 |w (DE-627)NLM199668515 |x 2150-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:09 |g month:02 |g pages:2301242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21505594.2023.2301242 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 09 |c 02 |h 2301242 | ||